Kenji Yamaoka

Onomichi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 18, 2025

Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients.

Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients.

Journal: Journal of gastroenterology

Published: April 11, 2025

Analysis of the treatment outcome of duodenal varices: A retrospective case series of 15 patients from a single institution.

Analysis of the treatment outcome of duodenal varices: A retrospective case series of 15 patients from a single institution.

Journal: DEN open

Published: March 05, 2025

Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Journal: Liver cancer

Published: February 19, 2025

Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.

Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.

Journal: Anticancer research

Published: January 30, 2025

Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model.

Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model.

Journal: JCO clinical cancer informatics

Published: December 18, 2024

Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma.

Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma.

Journal: Therapeutic advances in gastroenterology

Published: October 15, 2024

Cholesterol ensures ciliary polycystin-2 localization to prevent polycystic kidney disease.

Cholesterol ensures ciliary polycystin-2 localization to prevent polycystic kidney disease.

Journal: Life science alliance

Published: September 26, 2024

Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B.

Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B.

Journal: Journal of gastroenterology

Published: September 19, 2024

Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.

Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.

Journal: Medicine

Published: September 17, 2024

Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Journal: Journal of gastroenterology

Published: August 19, 2024

First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.

First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.

Journal: Oncology

Published: July 16, 2024

Showing 1-12 of 42

Last Updated: 09/26/2026